Incanthera, the drug development and targeted cancer medicines company, (“Incanthera” or “the Company”), is pleased to announce the results of its Strategic IP review, conducted in the first quarter of this year.
Firstly, pre-clinical in vitro and in vivo data on the Company’s most advanced programme, ICT01, are proving very encouraging and the Company is preparing the programme for a Phase I clinical trial.
ICT01 focuses on the development of a new anticancer agent, which has been dubbed a ‘smart bomb’. ICT01 releases a warhead when in contact with an enzyme that is specifically released by a cancer.
There is an essential need and appetite for technology to address the future of cancer treatment and therapeutics in this way and the Company is very pleased at the trial results received. Incanthera expects to be able to announce further details on timings of a Phase I trial in due course.
Additionally, the results of the IP portfolio review have resulted in the decision to maintain European patent protection across 21 European countries, effectively 99% of the European market place, for the Company’s lead asset, ICT01-2588, whilst progressing worldwide patent protection, to enhance existing markets including the United States and Japan. This strategic decision enhances ICT01-2588’s commercial value in the world’s second largest oncology market, estimated at US$30bn in 2018*
*Source: IMS Health MIDAS, Dec 2014, IMS Health Market Prognosis, March 2015
Simon Ward, Chief Executive Officer of Incanthera, commented:
“We are delighted at the results to date of the pre-clinical data of our most advanced programme, ICT01, and the Company’s lead asset, ICT01-2588 maintaining the maximum patent protection across the European market, whilst progressing that patenting into worldwide markets, provides a very valuable asset to spearhead the Company’s portfolio.
The global fight against cancer is showing incredible advances in technology and we are honoured to be at the forefront of ground breaking technology in oncology therapeutics.”
For further information, please contact:
Tim McCarthy, Chairman 07831 675747
Simon Ward, Chief Executive Officer 07747 625506
Suzanne Brocks 07776 234600
Notes to Editors
Established in 2010, Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.
Operating from Manchester, with research facilities in Bradford and Salford, Incanthera was established from the University of Bradford’s Institute of Cancer Therapeutics (www.cancer.brad.ac.uk) to develop oncology treatments from a low cost base via a productive pipeline of early stage technology opportunities.
Managed by a team of experienced individuals drawn from commercial, scientific and regulatory backgrounds, the team also has experience in the establishment, growth and exit of small to medium sized companies.
The website at www.incanthera.com has been designed to showcase the Company’s outstanding expertise in cancer therapeutic technologies.